Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Compound 114 (D3R/MOR antagonist 1) exhibits dual antagonistic activity at dopamine D3 receptors (D3R) and mu-opioid receptors (MOR), with K i values of 46.5 nM and 691 nM, respectively. It offers analgesic benefits through partial agonism at MOR and may decrease the risk of opioid misuse through its D3R antagonistic properties [1].
説明 | Compound 114 (D3R/MOR antagonist 1) exhibits dual antagonistic activity at dopamine D3 receptors (D3R) and mu-opioid receptors (MOR), with K i values of 46.5 nM and 691 nM, respectively. It offers analgesic benefits through partial agonism at MOR and may decrease the risk of opioid misuse through its D3R antagonistic properties [1]. |
分子量 | 420.38 |
分子式 | C22H27Cl2N3O |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
D3R/MOR antagonist 1 GPCR/G Protein Neuroscience Dopamine Receptor Inhibitor inhibitor inhibit